SHORT MINI FUTURE WARRANT - BRISTOL-MYERS SQUIBB | Real-time BOERSE MUENCHEN 11:55:44 24/06/2024 pm IST | ||
| 0.369 EUR | -15.17% |
|
| Current month | -21.82% | ||
| 1 month | -16.70% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24/24/24 | 0.369 | -15.17% |
| 21/24/21 | 0.435 | -12.65% |
| 20/24/20 | 0.498 | +3.11% |
| 19/24/19 | 0.483 | -3.01% |
| 18/24/18 | 0.498 | +2.26% |
Real-time BOERSE MUENCHEN
Last update June 24, 2024 at 11:55 pm IST
More quotesStatic data
| Product type | Knock-Out mit Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | Goldman Sachs |
| WKN | GG82W5 |
| ISIN | DE000GG82W50 |
| Date issued | 14/05/2024 |
| Strike | 46.15 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.1 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.565 € |
|---|---|
| Lowest since issue | 0.121 € |
| Spread | 0.01 € |
| Spread % | 2.70% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
42.23
USD
Average target price
53.19
USD
Spread / Average Target
+25.96%
- Stock Market
- Certificates
- Certificat
